AP2A1 and early-onset autosomal dominant Alzheimer disease: AP2A1 is a candidate biomarker gene among patients with ovarian cancer [74], pediatric medulloblastoma [75], and Alzheimer’s disease [76,77], suggesting that its aberrant expression can be pathological.